The use of relatively inexpensive generic drugs is a topical theme in pharmaceutical policy and regulation internationally. This paper addresses, first, the role of generics in international markets, and the experience of reference pricing programs. Second, the paper examines the development of generics policy in Australia, and seeks to
delineate, in broad terms, present policy challenges.